Sei Investments Co. Has $107.62 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Sei Investments Co. raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,449,377 shares of the medical equipment provider’s stock after purchasing an additional 26,849 shares during the period. Sei Investments Co. owned 0.62% of Hologic worth $107,617,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Innealta Capital LLC acquired a new stake in Hologic in the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic in the 1st quarter valued at $37,000. Cranbrook Wealth Management LLC acquired a new stake in shares of Hologic in the 2nd quarter valued at $47,000. Mather Group LLC. bought a new stake in Hologic in the first quarter worth $48,000. Finally, Massmutual Trust Co. FSB ADV increased its position in Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

NASDAQ:HOLX opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The company has a fifty day moving average price of $80.82 and a 200 day moving average price of $77.12. The stock has a market cap of $18.99 billion, a P/E ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the prior year, the business earned $0.93 earnings per share. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HOLX. Evercore ISI upped their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average target price of $87.60.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.